Is Regeneron Pharmaceuticals, Inc. Stock a Buy?
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller-coaster ride, though, with the stock plunging in 2016 but bouncing back somewhat this year.
What Regeneron has done in the past isn't nearly as important to investors as what the biotech could do in the future. Is the stock now a buy? Here are the arguments for and against Regeneron.
Image source: Getty Images.
Source: Fool.com
Sanofi S.A. ADR Aktie
52,00 €
-1,92 %
Deutliche Buy-Präferenz bei Sanofi S.A. ADR ohne Sell-Einschätzungen.
Ein leicht positives Kursziel von 55 € für Sanofi S.A. ADR gegenüber dem aktuellen Kurs von 52.0 € wird gesehen.
